Levothyroxine Sodium Tablet
FDA Recall NDC 16729-447

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

The FDA has identified 13 recorded enforcement report(s) associated with Levothyroxine Sodium (NDC 16729-447). A significant event, classified as Class II, was initiated on Sep 16, 2025 by Accord Healthcare Inc.. The reported reason for this action was: "Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range."

This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.

Reported Recall Events

September 2025 Class II Recall: Subpotent

Recall Number
Class II Ongoing
Reason for Recall
Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.
Initiated
Sep 16, 2025
Reported
Oct 15, 2025
Quantity
54,432 bottles

Recall Profile & Regulatory Data

Event ID
97613
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
ACCORD HEALTHCARE, INC.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide in the US
Product Description
Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 90 Tablets per bottle, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-450-15.
Batch or Lot Expiration Information
Lot# D2300045, Exp 12/31/2025.
Affected Packages Involved in this Recall
16729-458-15Product
16729-458-17Product
16729-447-15Product
16729-447-17Product
16729-448-15Product
16729-448-17Product
16729-449-15Product
16729-449-17Product
16729-451-15Product
16729-451-17Product
16729-450-15Product
16729-450-17Product
16729-452-15Product
16729-452-17Product
16729-453-15Product
16729-453-17Product
16729-454-15Product
16729-454-17Product
16729-455-15Product
16729-455-17Product
16729-456-15Product
16729-456-17Product
16729-457-15Product
16729-457-17Product

June 2025 Class II Recall: Subpotent Drug

Recall Number
Class II Ongoing
Reason for Recall
Subpotent Drug: Assay below the approved specification
Initiated
Jun 20, 2025
Reported
Jul 23, 2025
Quantity
4,921 bottles

Recall Profile & Regulatory Data

Event ID
97103
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
ACCORD HEALTHCARE, INC.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide in the USA
Product Description
Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg), 1000-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-455-17
Batch or Lot Expiration Information
Lot# D2300076, Exp Date: 12/31/2025
Affected Packages Involved in this Recall
16729-458-15Product
16729-458-17Product
16729-447-15Product
16729-447-17Product
16729-448-15Product
16729-448-17Product
16729-449-15Product
16729-449-17Product
16729-451-15Product
16729-451-17Product
16729-450-15Product
16729-450-17Product
16729-452-15Product
16729-452-17Product
16729-453-15Product
16729-453-17Product
16729-454-15Product
16729-454-17Product
16729-455-15Product
16729-455-17Product
16729-456-15Product
16729-456-17Product
16729-457-15Product
16729-457-17Product

June 2025 Class II Recall: Subpotent Drug

Recall Number
Class II Ongoing
Reason for Recall
Subpotent Drug: Assay below the approved specification
Initiated
Jun 20, 2025
Reported
Jul 23, 2025
Quantity
82,159 bottles

Recall Profile & Regulatory Data

Event ID
97103
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
ACCORD HEALTHCARE, INC.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide in the USA
Product Description
Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 90-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-447-15
Batch or Lot Expiration Information
Lot# D2300325, Exp Date: 01/31/2026
Lot# D2400536, Exp Date: 02/28/2026
Affected Packages Involved in this Recall
16729-458-15Product
16729-458-17Product
16729-447-15Product
16729-447-17Product
16729-448-15Product
16729-448-17Product
16729-449-15Product
16729-449-17Product
16729-451-15Product
16729-451-17Product
16729-450-15Product
16729-450-17Product
16729-452-15Product
16729-452-17Product
16729-453-15Product
16729-453-17Product
16729-454-15Product
16729-454-17Product
16729-455-15Product
16729-455-17Product
16729-456-15Product
16729-456-17Product
16729-457-15Product
16729-457-17Product

June 2025 Class II Recall: Subpotent Drug

Recall Number
Class II Ongoing
Reason for Recall
Subpotent Drug: Assay below the approved specification
Initiated
Jun 20, 2025
Reported
Jul 23, 2025
Quantity
2,344 bottles

Recall Profile & Regulatory Data

Event ID
97103
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
ACCORD HEALTHCARE, INC.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide in the USA
Product Description
Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), 1000-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-456-17
Batch or Lot Expiration Information
Lot# D2300042, Exp Date: 12/31/2025
Affected Packages Involved in this Recall
16729-458-15Product
16729-458-17Product
16729-447-15Product
16729-447-17Product
16729-448-15Product
16729-448-17Product
16729-449-15Product
16729-449-17Product
16729-451-15Product
16729-451-17Product
16729-450-15Product
16729-450-17Product
16729-452-15Product
16729-452-17Product
16729-453-15Product
16729-453-17Product
16729-454-15Product
16729-454-17Product
16729-455-15Product
16729-455-17Product
16729-456-15Product
16729-456-17Product
16729-457-15Product
16729-457-17Product

June 2025 Class II Recall: Subpotent Drug

Recall Number
Class II Ongoing
Reason for Recall
Subpotent Drug: Assay below the approved specification
Initiated
Jun 20, 2025
Reported
Jul 23, 2025
Quantity
9,739 bottles

Recall Profile & Regulatory Data

Event ID
97103
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
ACCORD HEALTHCARE, INC.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide in the USA
Product Description
Levothyroxine Sodium Tablets, USP, 100 mcg (0.1 mg), 1000-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-451-17
Batch or Lot Expiration Information
Lot# D2300092, Exp Date: 12/31/2025
Lot# D2400722, Exp Date: 03/31/2026
Affected Packages Involved in this Recall
16729-458-15Product
16729-458-17Product
16729-447-15Product
16729-447-17Product
16729-448-15Product
16729-448-17Product
16729-449-15Product
16729-449-17Product
16729-451-15Product
16729-451-17Product
16729-450-15Product
16729-450-17Product
16729-452-15Product
16729-452-17Product
16729-453-15Product
16729-453-17Product
16729-454-15Product
16729-454-17Product
16729-455-15Product
16729-455-17Product
16729-456-15Product
16729-456-17Product
16729-457-15Product
16729-457-17Product

June 2025 Class II Recall: Subpotent Drug

Recall Number
Class II Ongoing
Reason for Recall
Subpotent Drug: Assay below the approved specification
Initiated
Jun 20, 2025
Reported
Jul 23, 2025
Quantity
54,227 bottles

Recall Profile & Regulatory Data

Event ID
97103
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
ACCORD HEALTHCARE, INC.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide in the USA
Product Description
Levothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), 90-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-448-15
Batch or Lot Expiration Information
Lot# D2300087, Exp Date: 12/31/2025
Affected Packages Involved in this Recall
16729-458-15Product
16729-458-17Product
16729-447-15Product
16729-447-17Product
16729-448-15Product
16729-448-17Product
16729-449-15Product
16729-449-17Product
16729-451-15Product
16729-451-17Product
16729-450-15Product
16729-450-17Product
16729-452-15Product
16729-452-17Product
16729-453-15Product
16729-453-17Product
16729-454-15Product
16729-454-17Product
16729-455-15Product
16729-455-17Product
16729-456-15Product
16729-456-17Product
16729-457-15Product
16729-457-17Product

June 2025 Class II Recall: Subpotent Drug

Recall Number
Class II Ongoing
Reason for Recall
Subpotent Drug: Assay below the approved specification
Initiated
Jun 20, 2025
Reported
Jul 23, 2025
Quantity
2,352 bottles

Recall Profile & Regulatory Data

Event ID
97103
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
ACCORD HEALTHCARE, INC.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide in the USA
Product Description
Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 1000-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-447-17
Batch or Lot Expiration Information
Lot# D2400679, Exp Date: 02/28/2026
Affected Packages Involved in this Recall
16729-458-15Product
16729-458-17Product
16729-447-15Product
16729-447-17Product
16729-448-15Product
16729-448-17Product
16729-449-15Product
16729-449-17Product
16729-451-15Product
16729-451-17Product
16729-450-15Product
16729-450-17Product
16729-452-15Product
16729-452-17Product
16729-453-15Product
16729-453-17Product
16729-454-15Product
16729-454-17Product
16729-455-15Product
16729-455-17Product
16729-456-15Product
16729-456-17Product
16729-457-15Product
16729-457-17Product

June 2025 Class II Recall: Subpotent Drug

Recall Number
Class II Ongoing
Reason for Recall
Subpotent Drug: Assay below the approved specification
Initiated
Jun 20, 2025
Reported
Jul 23, 2025
Quantity
4,896 bottles

Recall Profile & Regulatory Data

Event ID
97103
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
ACCORD HEALTHCARE, INC.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide in the USA
Product Description
Levothyroxine Sodium Tablets, USP, 112 mcg (0.112 mg), 1000-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-452-17
Batch or Lot Expiration Information
Lot# D2300104, Exp Date: 12/31/2025
Affected Packages Involved in this Recall
16729-458-15Product
16729-458-17Product
16729-447-15Product
16729-447-17Product
16729-448-15Product
16729-448-17Product
16729-449-15Product
16729-449-17Product
16729-451-15Product
16729-451-17Product
16729-450-15Product
16729-450-17Product
16729-452-15Product
16729-452-17Product
16729-453-15Product
16729-453-17Product
16729-454-15Product
16729-454-17Product
16729-455-15Product
16729-455-17Product
16729-456-15Product
16729-456-17Product
16729-457-15Product
16729-457-17Product

April 2025 Class II Recall: Subpotent

Recall Number
Class II Ongoing
Reason for Recall
Subpotent
Initiated
Apr 10, 2025
Reported
May 07, 2025
Quantity
4,885 Bottles

Recall Profile & Regulatory Data

Event ID
96666
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
ACCORD HEALTHCARE, INC.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide US.
Product Description
Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 1000 bottles, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, INDIA, NDC 16729-450-17
Batch or Lot Expiration Information
Lot# D2300044, Exp Date: 12/2025
Affected Packages Involved in this Recall
16729-458-15Product
16729-458-17Product
16729-447-15Product
16729-447-17Product
16729-448-15Product
16729-448-17Product
16729-449-15Product
16729-449-17Product
16729-451-15Product
16729-451-17Product
16729-450-15Product
16729-450-17Product
16729-452-15Product
16729-452-17Product
16729-453-15Product
16729-453-17Product
16729-454-15Product
16729-454-17Product
16729-455-15Product
16729-455-17Product
16729-456-15Product
16729-456-17Product
16729-457-15Product
16729-457-17Product

April 2025 Class II Recall: Subpotent

Recall Number
Class II Ongoing
Reason for Recall
Subpotent
Initiated
Apr 10, 2025
Reported
May 07, 2025
Quantity
18,984 Bottles

Recall Profile & Regulatory Data

Event ID
96666
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
ACCORD HEALTHCARE, INC.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide US.
Product Description
Levothyroxine Sodium Tablets, USP, 112 mcg (0.112 mg), 90 bottles, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, INDIA, NDC 16729-452-15
Batch or Lot Expiration Information
Lot# D2400725, Exp Date: 03/2026
Affected Packages Involved in this Recall
16729-458-15Product
16729-458-17Product
16729-447-15Product
16729-447-17Product
16729-448-15Product
16729-448-17Product
16729-449-15Product
16729-449-17Product
16729-451-15Product
16729-451-17Product
16729-450-15Product
16729-450-17Product
16729-452-15Product
16729-452-17Product
16729-453-15Product
16729-453-17Product
16729-454-15Product
16729-454-17Product
16729-455-15Product
16729-455-17Product
16729-456-15Product
16729-456-17Product
16729-457-15Product
16729-457-17Product

April 2025 Class II Recall: Subpotent

Recall Number
Class II Ongoing
Reason for Recall
Subpotent
Initiated
Apr 10, 2025
Reported
May 07, 2025
Quantity
4,872 Bottles

Recall Profile & Regulatory Data

Event ID
96666
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
ACCORD HEALTHCARE, INC.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide US.
Product Description
Levothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), 1000 bottles, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, INDIA, NDC 16729-448-17.
Batch or Lot Expiration Information
Lot# D2400547, Exp Date: 02/2026
Affected Packages Involved in this Recall
16729-458-15Product
16729-458-17Product
16729-447-15Product
16729-447-17Product
16729-448-15Product
16729-448-17Product
16729-449-15Product
16729-449-17Product
16729-451-15Product
16729-451-17Product
16729-450-15Product
16729-450-17Product
16729-452-15Product
16729-452-17Product
16729-453-15Product
16729-453-17Product
16729-454-15Product
16729-454-17Product
16729-455-15Product
16729-455-17Product
16729-456-15Product
16729-456-17Product
16729-457-15Product
16729-457-17Product

April 2025 Class II Recall: Subpotent

Recall Number
Class II Ongoing
Reason for Recall
Subpotent
Initiated
Apr 10, 2025
Reported
May 07, 2025
Quantity
4,888 Bottles

Recall Profile & Regulatory Data

Event ID
96666
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
ACCORD HEALTHCARE, INC.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide US.
Product Description
Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 1000 bottles, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, INDIA, NDC 16729-447-17
Batch or Lot Expiration Information
Lot# D2300323, Exp Date: 01/2026
Affected Packages Involved in this Recall
16729-458-15Product
16729-458-17Product
16729-447-15Product
16729-447-17Product
16729-448-15Product
16729-448-17Product
16729-449-15Product
16729-449-17Product
16729-451-15Product
16729-451-17Product
16729-450-15Product
16729-450-17Product
16729-452-15Product
16729-452-17Product
16729-453-15Product
16729-453-17Product
16729-454-15Product
16729-454-17Product
16729-455-15Product
16729-455-17Product
16729-456-15Product
16729-456-17Product
16729-457-15Product
16729-457-17Product

November 2024 Class II Recall: Subpotent drug

Recall Number
Class II Ongoing
Reason for Recall
Subpotent drug
Initiated
Nov 08, 2024
Reported
Dec 11, 2024
Quantity
N/A

Recall Profile & Regulatory Data

Event ID
95747
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
ACCORD HEALTHCARE, INC.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
USA Nationwide
Product Description
Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 1000-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, INDIA, NDC 16729-449-17
Batch or Lot Expiration Information
Lot# : D2300191, Exp 12/31/2025
Affected Packages Involved in this Recall
16729-458-15Product
16729-458-17Product
16729-447-15Product
16729-447-17Product
16729-448-15Product
16729-448-17Product
16729-449-15Product
16729-449-17Product
16729-451-15Product
16729-451-17Product
16729-450-15Product
16729-450-17Product
16729-452-15Product
16729-452-17Product
16729-453-15Product
16729-453-17Product
16729-454-15Product
16729-454-17Product
16729-455-15Product
16729-455-17Product
16729-456-15Product
16729-456-17Product
16729-457-15Product
16729-457-17Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.